Skip to main content

Combinatorial immunization strategy to educate the immune system towards cross recognition and coverage against antigenic drift in seasonal influenza virus exposure

Objetivo

As current influenza vaccines only afford limited protection against seasonal as well as pandemic influenza, and require regular updating, the development of a “universal” influenza vaccine that can provide broad coverage against different strains within a subtype or even across subtypes has become a key health care priority in both industrialized and low and middle income countries. EDUFLUVAC aims to develop an influenza vaccine that educates the immune system to recognise common influenza epitopes, using a combination of influenza haemagglutinin (HA) antigens delivered on a single virus-like particle. This vaccine concept, using the proven, modern technology of baculovirus VLPs will enable enhanced cross linking of B-cell receptors and favour induction of B-cell responses against common epitopes essential for long-lasting cross recognition and protection. The mechanism underlying the broadening of antibody responses is the increased relative concentration of common epitopes diluting out strain specific epitopes. This will be achieved by testing the ability of a combination of historic HA variants to protect against a variety of modern isolates. A similar approach for developing a novel vaccine for pandemic use will be tested. The knowledge generated will provide Proof of Principle in relevant animal models for an influenza vaccine that does not have to be updated annually, does not have to be manufactured on an annual basis and will not require an annual vaccination campaign. It will also provide for an economically viable large scale production platform for influenza vaccine which, in the event of a pandemic, can manufacture rapidly high quantities of vaccine. All industrial partners (including two SMEs) will benefit from the compilation of the regulatory dossier for transfer to larger vaccine companies and the deeper knowledge integration emanating from EDUFLUVAC in a $2.8 billion global annual influenza vaccine market.

Ámbito científico

  • /ciencias médicas y de la salud/ciencias de la salud/enfermedad infecciosa/virus ARN/gripe
  • /ciencias médicas y de la salud/medicina básica/inmunología

Convocatoria de propuestas

FP7-HEALTH-2013-INNOVATION-1
Consulte otros proyectos de esta convocatoria

Régimen de financiación

CP-FP - Small or medium-scale focused research project
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinador

EUROPEAN VACCINE INITIATIVE EWIV
Dirección
Vossstrasse 2 Geb 4040
69115 Heidelberg
Alemania
Tipo de actividad
Research Organisations
Aportación de la UE
€ 930 000
Contacto administrativo
Odile Leroy (Dr.)

Participantes (6)

REDBIOTEC AG
Suiza
Aportación de la UE
€ 716 780
Dirección
Wagistrasse 23
8952 Schlieren
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Christian Schaub (Mr.)
INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA
Portugal
Aportación de la UE
€ 1 263 336
Dirección
Avenida Da Republica Quinta Do Marques
2781-901 Oeiras
Tipo de actividad
Research Organisations
Contacto administrativo
Elsa Vieira (Dr.)
ETNA BIOTECH SRL
Italia
Aportación de la UE
€ 240 000
Dirección
Strada Vincenzo Lancia 57
95100 Catania
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Antonio Di Mauro (Mr.)
STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER
Países Bajos
Aportación de la UE
€ 983 670
Dirección
Lange Kleiweg 161
2288 GJ Rijswijk Zh
Tipo de actividad
Research Organisations
Contacto administrativo
Willem Slingerland (Mr.)
STICHTING WAGENINGEN RESEARCH
Países Bajos
Aportación de la UE
€ 374 250
Dirección
Droevendaalsesteeg 4
6708 PB Wageningen
Tipo de actividad
Research Organisations
Contacto administrativo
Norbert Stockhofe (Dr.)
Department of Health
United Kingdom
Aportación de la UE
€ 139 113
Dirección
Quarry House, Quarry Hill
LS2 7UE Leeds
Tipo de actividad
Research Organisations
Contacto administrativo
Amanda King (Mrs.)